Are you looking for expert advice...

As clinicians committed to the advancement of medical cannabis treatment, staying at the forefront of patient care is a constant pursuit. The Society (MCCS) champions the integration of medical cannabis into patient management, advocating for evidence-based application.

For those members eager to expand their private practice with medical cannabis prescribing, Script Assist’s Find A Doctor service stands as a transformative resource designed to elevate your clinical practice.

Streamline Your Workflow & Improve Efficiency: Say goodbye to administrative headaches and inefficiencies. With Script Assist’s live inventory feature, you can easily manage product availability and streamline prescription updates in real-time. Our printable FP10s ensure accurate and efficient prescription management, minimizing errors and maximizing patient safety. Furthermore, our one-click re-prescribing feature simplifies monthly re-prescribing, ensuring efficient clinic workflows and patient satisfaction.

Empowering Patients and Enhancing Engagement: Empower your patients with the tools they need to take control of their healthcare journey. With Script Assist’s Patient App, patients can book appointments, attend telehealth consultations, and track prescriptions—all from the convenience of their smartphone. This not only improves patient satisfaction but also reduces the administrative burden on your practice.

Collaboration at Your Fingertips: Collaborative care is essential for providing comprehensive treatment plans. With Script Assist, you can access Multidisciplinary Team Reviews for any new or complex patients, to ensure alignment with GMC guidance. Not only that, but you can easily add medical secretaries, clinic admins, and other healthcare professionals to facilitate re-prescribing and streamline clinic operations.

Customise Your Experience to Suit You: At Script Assist, we understand that every practice and every doctor is unique. That’s why our platform is fully customisable, allowing you to tailor it to your practice’s specific needs. Whether you’re replacing existing software packages or integrating Script Assist seamlessly into your current workflow, we’ve got you covered.

Expand Your Reach & Maintain Control: As members of Script Assist’s Find A Doctor platform, you gain access to a vast network of patients seeking medical cannabis treatment. Expand your practice and engage with patients directly, all while maintaining complete control over your schedule and practice scale. With full visibility of patients prior to engagement, you can provide personalized care from the moment they walk through your door.

Taking the Next Step

The introduction of Find A Doctor goes beyond creating a directory for patients to find specialists; it offers specialists a chance to enhance their practice’s visibility and connect with patients seeking comprehensive care that includes medical cannabis. Joining signifies more than access to a streamlined portal; it’s about broadening your practice’s reach and affirming your dedication to patient-focused care.

By leveraging Script Assist’s Find A Doctor, you not only streamline your practice’s operations but also play a pivotal role in the progressive integration of medical cannabis into mainstream healthcare. It’s an invitation to join a community of forward-thinking clinicians who are shaping the future of patient care in the UK. Don’t wait to take your practice to the next level with Script Assist’s Find A Doctor — a step towards enhancing patient outcomes across the UK.

Speak to Script Assist today; sales@scriptassist.co.uk

The Medical Cannabis Clinicians Society (MCCS) is excited to support an essential event in the world of medical cannabis – the International Conference on the Science & Practice of Medical Cannabis (CT-Cann2024).

This prestigious conference is set to take place in London on the 29th and 30th of May, 2024, at the Hilton London Canary Wharf. Our endorsement of CT-Cann2024 highlights our commitment to advancing research and clinical practice in medical cannabis.

A landmark cannabis event

Last year’s conference was a landmark event, bringing together clinicians and experts for a rich dialogue on the latest developments in the field.

The Society is proud to have supported this vibrant forum, which made significant strides in medical cannabis discussions.

This year, the event has been renamed to International Conference on the Science & Practice of Medical Cannabis (CT-Cann2024) to reflect the growing scope of discussions around cannabis research and its practical applications in healthcare.

What’s in Store at CT-Cann2024

CT-Cann2024 is a forward-thinking platform for cannabinoid therapy advances. Led by co-chairs Prof. Dedi Meiri and Dr. Haggai Sharon, the event is set to showcase the most recent evidence and ideas in cannabinoid therapy.

The conference will bridge the latest scientific discoveries with clinical practices, providing insights into the effective use of cannabinoid-based treatments. It offers a unique chance for attendees to meet leading researchers, clinicians, and industry professionals from around the world, creating a space for the exchange of innovative ideas and practices.

Special Offer for MCCS Members

To show our appreciation for our members’ dedication to the field of medical cannabis, the MCCS is pleased to offer a special 15% discount on registration rates for CT-Cann2024.

This exclusive discount is our way of saying thank you to our members for their ongoing support and commitment.

Members who wish to take advantage of this offer should contact Rachel at rachel@bioevents-congress.com for more details and the discount code.

Join Us in London

As CT-Cann2024 draws near, we warmly invite our members and the broader community to join this significant event. Whether you’re a seasoned clinician, a researcher at the cutting edge of cannabis science, or an industry professional interested in the latest trends and applications, CT-Cann2024 promises to be an enlightening experience.

Let’s come together in London for CT-Cann2024, to be at the forefront of shaping the future of medical cannabis.

The UK medical cannabis market has, for the most part, largely been characterised by patients having to turn to medical cannabis clinics for their medical cannabis prescriptions. Launched in April 2023, Script Assist was established to let any specialist prescribe medical cannabis from any private setting, for the first time enabling independent doctors to efficiently enhance their own private practise.

Earlier this month Script Assist 2.0 was released, containing a host of new features to enable independent prescribers to prescribe medical cannabis from any private setting.

We caught up with Hannah Simon, Script Assist’s COO, to understand her views on how Script Assist 2.0 revolutionises the UK medical cannabis prescription market for private prescribers.

Thanks for taking the time to speak to us Hannah. Could you please start off by explaining what Script Assist is, and how you support independent private prescribers?

Script Assist is a free Web Portal for doctors and their secretaries, that alongside a Patient App, enables an easy, seamless experience for all parties.

Script Assist automates all compliance and administrative tasks, has a formulary with live inventory, includes access to a free MDT and medical cannabis products are dispensed to patients via the Patient App.

This means that any specialist in the UK can now effortlessly prescribe medical cannabis to their patients from their own private practise.

We are licensed by the Home Office, the MHRA and the GPhC to undertake each step of the distribution and dispensing journey in the UK, which is why we can offer such an integrated, seamless experience.

What has changed with Script Assist 2.0, why is it so revolutionary?

Script Assist 1.0 was focussed on the basics: for us that meant digitising the entire prescription process from initiation through to dispensing, whilst ensuring strict adherence to GMC guidance. The licensing and software engineering elements of Script Assist 1.0 took around three years, but the result was a step-change for independent prescribers in the UK.

When doctors started using Script Assist 1.0, we learned a huge amount about how we could make the experience even more seamless, and that by broadening the scope of the technology, we can make Script Assist 2.0 an even more powerful tool.

First, Script Assist 1.0 was a tool for doctors. Script Assist 2.0 is a tool for doctors, medical secretaries and whomever else supports the doctor in their practise and can be used totally flexibly reflecting however the practise operates today. Limiting & removing administrative tasks from the doctor’s plate is one of our North Stars at Script Assist!

Script Assist 2.0 also has a lot more features. For example, printable FP10s, one-click represcribing, optional booking and telehealth via the Patient App, more extensive PROM frameworks, a much broader research library, the ability for doctors to work across multiple sites, and lot, lot more.

You’ve explained a lot about the technology itself, and it seems like you’ve solved the technical problems, what other support do you offer independent prescribers?

Well, as you know we work closely with yourselves at the MCCS to provide doctors with all the support that they require. We have trained between ourselves over 100 doctors since our launch, and we have another 30 signed up to our November Psychiatry training.

We also offer a whole host of day-to-day support to all our doctors for free. As a licensed company, we take regulations pretty seriously and so we offer a lot of regulatory support to our doctors to help them understand the parameters within which they can prescribe – and we cover everything; from the CQC, to FP10 applications, to Insurance etc.

In addition, all new Script Assist doctors are offered a buddy, and we also use the MDT sessions to provide a range of additional support services to our clinicians. For example, a Script Assist enabled doctor can submit a patient to the MDT and simply ask for guidance on what and how to prescribe, if they so wish.

We also offer live technical support, and our Script Assist customer service agents can access your session live to help you with any problems or questions you may have.

What does a private prescriber need to start prescribing medical cannabis from their private practise?

An independent prescriber must also work part-time in a clinic covered by the CQC (this can be as simple as being employed by the NHS).

They require a pink FP10 pad for Controlled Drugs prescribing (I have helped almost 100 doctors submit FP10 applications over the years and am more than happy to help anyone through this process!) and must add medical cannabis prescribing onto their medical indemnity insurance (again, I can help with this!). Other that that they need a DBS certificate, a GMC number and a passport or driver’s license!

Finally, a Script Assist account would make their lives a whole lot easier!

Does the CQC not need to be notified if an independent prescriber starts prescribing?

Independent doctors with practising privileges can prescribe medical cannabis in their private practice the same way as they prescribe any other medicine today. So in short the answer to this question is no. The CQC only need to be notified if a clinic/ hospital that is already covered by the CQC want to advertise medical cannabis prescribing as a service offering.

Can Script Assist help independent prescribers grow the number of patients in their practise?

In January we will be launching our Find a Doctor functionality. This means that on the Script Assist website patients will be able to view a directory of Script Assist enabled doctors, alongside the conditions for which they prescribe, their consultation rates, insurers (if patients have private medical insurance then consultations are covered as any other consultation would be) and other key information.

Patients will then be able to submit their profile and medical records (soon available digitally on Script Assist) to a clinician and request an initial consultation. We will be having a pretty extensive patient launch, it’s all rather exciting!

Thanks to Hannah Simon for taking the time to speak to us. We wish her and Script Assist well with the release of Script Assist 2.0 and their mission to empower independent prescribers in the UK.

 

On 2 November 2023, as part of Medical Cannabis Awareness Week, the Cannabis Industry Council and the Medical Cannabis Clinicians Society is hosting an exclusive networking event in London.

Hosted at Gowling WLG, attendees will have the opportunity to meet and interact with a diverse, influential audience.

About the Event

Speakers

Dr. Dedi Meiri directs the Laboratory of Cancer Biology
and Cannabinoid Research, investigating cannabinoids’ therapeutic potential on diseases like cancer and epilepsy and spearheads the Database Project, profiling diverse cannabis strains and their medical relevance.

We are currently in the process of confirming a panel of speakers, with a keen emphasis on creating dynamic and thought-provoking conversations for our guests.

Over the next few weeks, we will continue our efforts in securing a range of additional high-profile speakers, offering a broad spectrum of expertise and viewpoints. The event will be a unique opportunity, open exclusively to leading stakeholders, including business leaders, MPs, policymakers and investors.

Sponsorship opportunities

As a sponsor, you will enjoy unparalleled exposure to an audience of industry professionals, clinicians, and influential stakeholders in the cannabis sector.

Support as a sole sponsor with a 15 minute speaking slot plus a range of other benefits.

To learn more and request the sponsorship packages in detail, please contact Hannah Deacon at contact@ukmccs.org.

The Medical Cannabis Clinicians Society (MCCS) and Volteface have been successfully elected as the new secretariat for the Medical Cannabis under Prescription APPG – bringing new bold strategy and commitment to working collaboratively with parliament, the industry and patients to improve the UK landscape.

Since legalisation of medical cannabis in 2018 a number of significant barriers have formed – from a lack of awareness to the continued struggle of paediatric access. The tireless work of MPs in the APPG to date to raise awareness of these issues in parliament has been challenging and at times been met with strong opposition from the government. The new focus of the APPG seeks to find allies both in and out of parliament who can provide evidence-based and practical solutions to overcoming the existing barriers.

These areas of focus include:

  1. Awareness amongst the British public that it is available on prescription
  2. Policy model in place is limiting and should explore broader prescribing (i.e. GPs)
  3. Number of prescribing clinicians and the hesitancies cannabis-naïve clinicians face
  4. Competition with the illicit market in regards to pricing, quality, distribution and cultivation
  5. Stigma among the British public, exploring how medical cannabis can appropriately fit into mainstream healthcare
  6. Highlighting the challenges of paediatric access. Families are faced with very high costs compared to adult patients and a lack of prescribers.

The new secretariat offers a vast amount of industry and medical cannabis expertise. Volteface and MCCS have an expansive network across politics, mainstream media, the clinical sphere, the cannabis industry, patients and advocacy groups.

Both organisations have a deep understanding of the sector and the issues facing it. With this expertise they are well positioned to help instigate adequate change.

The secretariat feels particularly strongly about collaborating with patient groups to ensure their needs are addressed and are a centre point for engaging Westminster on the issue. Alongside this, as professionals in the sector, Volteface and MCCS wants to ensure that the industry is positioned appropriately within parliament and has a voice to raise pertinent issues around the sustained development of the sector.

Tonia Antoniazzi, Labour MP and co-chair of the APPG for medical cannabis under prescription said: “As co-chair of the APPG I’m delighted to welcome Volteface and The Medical Cannabis Clinicians Society as the new secretariat of the group. Volteface and the MCCS have a wide range of expertise which will be extremely valuable moving forward.

Progress has been slow since the law change almost 5 years ago, so it is vital that we keep this conversation alive. I’m looking forward to working alongside our new secretariat in addressing the barriers to accessing medical cannabis under prescription and I hope we can start to see change happen.”

Leon Barron, Chair of the Medical Cannabis Clinicians Society said: “I am delighted that the MCCS along with Volteface have been appointed as secretariat to the APPG on medical cannabis. We look forward to moving this conversation forwards and to bridge the gap between policy makers, clinicians, and academics. Medical cannabis is being utilised widely across the globe and has proven efficacy for a range of chronic conditions. It can play a crucial role in relieving suffering and enhancing overall quality of life.  Our priority must be to find pragmatic solutions to the barriers that are restricting eligible patients in the UK accessing these medicines and we must ensure that all doctors, including GPs feel well informed and confident in prescribing medical cannabis.”

Hannah Deacon Executive Director of the Medical Cannabis Clinicians Society said: “It is an honour to be appointed secretariat to the APPG on medical cannabis. I am excited to be working with Volteface who have proven experience in this area and together I feel we will make an important contribution to ensuring the APPG continues to push forward to issues that patients, clinicians and the medical cannabis industry face. I know only too well of the suffering that patients continue to endure and the difficulties clinicians face in trying to access this prescribable medicine for their patients. I hope working together we can help move things forward to a place where patients and clinicians are better served and the industry is able to function in a more streamlined manner.”

Paul North, Director of Volteface said: “It is imperative that we work together to improve medical cannabis access and prescribing in the UK. The key to that collaboration is through parliament – an environment which can facilitate learning, find solutions to complex problems and lead to the formation of effective policy. Volteface has been engaging MPs and policy makers since its inception in 2017 and we are well aware of the challenges that lie ahead of us. Alongside our friends and colleagues at MCCS we are determined to provide MPs with the resources, knowledge and steer they need to improve medical cannabis prescribing in the UK.”

Katya Kowalski, Head of Operations of Volteface said: “I’m thrilled to be working with the APPG and the MCCS to advance the conversation around medical cannabis in parliament. Working in the sector it has been so frustrating to see the dialogue stagnate politically. There is still so much that needs to be done, particularly around effectively communicating the state of play to policy makers to raise awareness about the legality and accessibility of this medicine. There are a multitude of issues that need to be addressed for the sector to thrive and for patients to be tended to, and I look forward to advancing this through our role within the APPG.”

 

We are pleased to share the details of a new training opportunity brought to you by ScriptAssist, a dedicated supporter of the Medical Cannabis Clinicians Society (MCCS).

ScriptAssist and MCCS share a common goal of broadening access to medical cannabis treatments through education and straightforward prescribing. ScriptAssist, in collaboration with MCCS, is presenting a series of invaluable training sessions for specialist consultants keen to enhance their knowledge and skills in cannabis medicine.

Training Sessions: What to Expect

The training days are structured into three comprehensive sessions, each lasting three hours. They are designed to offer a deep dive into specific healthcare disciplines of psychiatry, neurology and pain.

Each session begins with an in-depth overview of cannabis as a treatment, including an exploration of its varied uses, potential contraindications, side effects, and the different delivery routes available, presented by MCCS Chair, Dr. Leon Barron.

Following that, Dr. Mark Smith, ScriptAssist’s Clinical Advisor, will present indication-specific case studies alongside guest presenters. Each case study offers real-world insights into the use of medical cannabis in treatment, providing invaluable context and deepening understanding.

To conclude the session, attendees will gain practical insights on how to apply all the knowledge gained in a real-life, private practice setting. Arjun Rajyagor, Founder and CTO of ScriptAssist, using the ScriptAssist platform as a tool, will demonstrate the journey from learning to application, showcasing the seamless integration of the platform in facilitating medical cannabis prescribing.

Tuesday, 13th June

The Royal Society of Medicine, 1 Wimpole Street, London, W1G 0AE

Psychiatry, 10am – 1pm

With guest presenter Dr Niraj Singh, Consultant Psychiatrist and Expert Member of the Society.

Neurology, 2pm – 5pm

With guest presenter Dr Elie Okirie, Consultant in Neurological and Specialist Rehabilitation and Expert Member of the Society.

Pain, 6pm – 9pm

With guest presenter Dr Dani Gordon, Integrative Medicine & Cannabis Medicine Consultant and Vice-Chair of the Society

About ScriptAssist

ScriptAssist empowers clinicians to prescribe medical cannabis seamlessly as part of their private practice for the first time. As a free-to-use governance tool, ScriptAssist integrates a dedicated patient app with a data-driven formulary. It is a platform meticulously designed for specialist clinicians to prescribe medical cannabis safely, effectively, and confidently.

Since January 2023, ScriptAssist has been a trusted supporter of the Society.

Don’t miss this opportunity to broaden your understanding and skills in prescribing medical cannabis. Book your spot in the upcoming training sessions today..
Book Your Place

The Medical Cannabis Clinicians Society is proud to announce our support for a new campaign called “Protect Our Patients.” This vital campaign, led by the Cannabis Industry Council (CIC), aims to extend the legal access to medical cannabis in the United Kingdom. Currently, 1.8 million patients rely on the illicit market for their medical cannabis needs, and we believe it’s time to change that.

In 2018, then Home Secretary Sajid Javid MP introduced new rules allowing specialist medical practitioners, but not general practitioners (GPs), to prescribe cannabis medicines. This change resulted in about 1,000 patients receiving cannabis prescriptions through the NHS annually, with an additional 20,000 patients obtaining private prescriptions each year.

However, these numbers pale in comparison to the 1.8 million people in the UK accessing the illicit cannabis market for medical reasons. This issue stems, in part, from the fact that GPs are unable to prescribe medical cannabis and the prohibitive cost of private prescriptions for those on low incomes or disability benefits.

The Protect Our Patients campaign calls for a change in policy, allowing GPs to prescribe medical cannabis to their patients. This relatively straightforward change would greatly benefit countless patients in need. The campaign is seeking support from various industry organisations, including the Society, Volteface, and Maple Tree Consultants, to rally behind this critical initiative.

Soicety Founder and CIC President, Professor Mike Barnes, highlighted the importance of the campaign, stating, “The current model for medical cannabis where only consultants can prescribe is simply not working in the interests of the majority of patients.” He urged the industry to unite around this agenda to better protect patients in need.

The Society fully supports the Protect Our Patients campaign and GP prescribing of medical cannabis. We also welcome GPs as members of our Society, recognising the essential role they play in patient care.

To support the campaign, you can share its details, including the video, on your social media channels using #ProtectOurPatients.

Visit the website at www.protectourpatients.co.uk for more.

Together, we can advocate for more accessible medical cannabis and ensure that patients receive the care they deserve. Let’s work together to make medical cannabis more widely available and help patients access the medicine they so desperately need.

We are delighted to extend a warm welcome to our newest supporter, Althea. Their commitment to our cause further strengthens our mission and reinforces the importance of collaboration within the medical cannabis sector.

Meet Althea

Althea, a global pharmaceutical company, specialises in distributing medicinal cannabis products to various markets such as the United Kingdom, Ireland, Germany, Australia, and South Africa. They use their extensive expertise to collaborate with healthcare professionals, educating them on the clinical usage of medicinal cannabis and simplifying prescribing pathways to achieve the best clinical outcomes for patients.

Proudly offering Concierge, a Therapeutic Goods Administration-registered medical device, Althea delivers a range of education, access, and management tools to assist healthcare professionals and eligible patients in navigating medicinal cannabis treatment pathways. To learn more, one can register for Concierge here: Login – Althea Concierge, or contact medinfo.uk@althea.life.

We are proud to offer Concierge, a Therapeutic Goods Administration-registered medical device, which provides a range of education, access, and management tools to support healthcare professionals and eligible patients in navigating medicinal cannabis treatment pathways. To learn more, register for Concierge at the following link Login – Althea Concierge or contact medinfo.uk@althea.life.

Focusing on quality and consistency, Althea’s comprehensive portfolio of full-spectrum products is manufactured in accordance with Good Manufacturing Practice regulations. The company believes in the potential value of the entourage effect offered by full-spectrum products (*1&2).

For more information about Althea, their product portfolio, and the services they provide, please reach out to them at medinfo.uk@althea.life.

 

Supporting the MCCS

The Medical Cannabis Clinicians Society is grateful for the continued support from licensed producers, industry leaders, and individuals alike, which enables us to achieve our objectives.

This generous unrestricted educational grant funding empowers the Society to offer CPD-accredited training, events, and peer support, fostering the development and expansion of the UK’s largest and most esteemed network of prescribers.

Organizations interested in collaborating with the Society are encouraged to reach out and discover the advantages of joining forces to enhance our collective impact.

 

References

1. Russo, E., 2019. The Case for the Entourage Effect and Conventional Breeding of Clinical Cannabis: No “Strain,” No Gain. Frontiers in Plant Science, 9.
2. Baron, E., 2018. Medicinal Properties of Cannabinoids, Terpenes, and Flavonoids in Cannabis, and Benefits in Migraine, Headache, and Pain: An Update on Current Evidence and Cannabis Science. Headache, 58(7), pp.1139-1186.

A Three-Part Webinar Series by the Medical Cannabis Clinicians Society

As medical cannabis continues to gain recognition as a potential treatment option for various health conditions, it’s essential for healthcare professionals to stay informed and educated. The Medical Cannabis Clinicians Society is proud to present a three-part webinar series designed to provide medical professionals with a comprehensive overview of medical cannabis pharmacology, UK regulations, practical prescribing considerations, and the multidisciplinary team (MDT) approach to prescribing.

Led by members of the Society’s Expert Committee, these engaging webinars will offer evidence-based insights, practical guidance, and real-world case discussions to help medical professionals deepen their understanding of medical cannabis and its potential applications. Whether you’re a doctor, nurse, medical student, or pharmacist, this exclusive webinar series offers a unique opportunity to learn from leading experts in the field and join a supportive community of like-minded professionals interested in advancing their knowledge in medical cannabis.

Each webinar in the series will focus on different aspects of medical cannabis, providing a well-rounded educational experience for healthcare professionals who are interested in incorporating medical cannabis into their practice.

 

2023 Webinar 1

An Introduction to Medical Cannabis for Healthcare Professionals

This webinar is the first in a series of three webinars that are specifically designed to provide medical professionals with a comprehensive understanding of medical cannabis. Join us for an engaging and informative introduction to medical cannabis pharmacology and UK regulations, designed specifically for medical professionals who are curious about this emerging field. Whether you’re a doctor, nurse, medical student, or pharmacist, this webinar will provide you with a comprehensive overview of medical cannabis and its applications in clinical practice in the UK.

During this webinar, you’ll have the opportunity to learn from leading experts in the field of medical cannabis, who will share their insights and knowledge on topics including:

This webinar will be delivered in an engaging and interactive format, with opportunities for Q&A sessions with the experts, allowing you to get your questions answered by leading professionals in the field.

Register here

 

Webinar 2

The Practicalities of Prescribing Medical Cannabis

In the second webinar of the series, we will dive into the practicalities of prescribing medical cannabis as a GMC registered Specialist (Consultant). This webinar will cover important topics such as applying for an FP10 license, understanding insurance considerations, and dosing guidelines. Our expert speakers will provide insights and guidance on navigating the regulatory requirements and practical considerations of prescribing medical cannabis, ensuring that doctors are equipped with the knowledge and tools needed to confidently prescribe medical cannabis in their practice.

Register here

 

Medical Cannabis MDT Review – Real Cases Discussed with Expert Clinicians

The third webinar in the series will provide a unique opportunity to understand the multidisciplinary team (MDT) approach to prescribing medical cannabis. Through real cases discussed with expert clinicians, attendees will gain valuable insights into how medical cannabis is integrated into a holistic treatment plan, involving a collaborative effort between various healthcare professionals. This webinar will provide a comprehensive understanding of the MDT approach to prescribing medical cannabis, covering the practical, ethical, and legal considerations involved in the decision-making process.

Register here

 

Sign up for all three webinars

Certificates of attendance will be provided for professional development purposes. Don’t miss out on this exclusive series of webinars designed to provide medical professionals with comprehensive knowledge and practical insights on medical cannabis. Register now to secure your spot for all three webinars and stay ahead in this rapidly evolving field of medicine.

Introducing the Medical Cannabis Clinicians Society

The Medical Cannabis Clinicians Society is a not-for-profit membership organization dedicated to supporting clinicians in the UK who are interested in advancing their understanding of medical cannabis.

With a mission to promote education, research, and best practices in medical cannabis, the Society provides a platform for clinicians to access support from experts in the field and connect with peers who share a common interest in this emerging area of medicine. The Society is committed to promoting evidence-based, patient-centred care and fostering a community of medical professionals who are at the forefront of medical cannabis education and practice in the UK.

 

The Medical Cannabis Clinicians Society maintains a list of available cannabis-based medical products regularly updated and shared with its members.

As a member of the Medical Cannabis Clinicians Society, clinicians are supported with all the practical guidance they need prescribe medical cannabis safely, including training, education, peer and expert support and mentoring, FAQs and access to an accurate product list of available medications.

In the latest update for members, we have included new products available for the first time in the UK from Stenocare via Rokshaw and PCCA Ltd. Stenocare, founded in 2017, cultivates, produces, imports and sells prescription-based medical cannabis, focusing on Patient Safety, Affordability & Accessibility. In 2018, Stenocare became the first Danish company to obtain all permits to cultivate, import and trade in medicinal cannabis oils in the Danish pilot program. Stenocare is the only Danish company that has succeeded in having medical oil-based cannabis products approved for the Danish pilot program and supplies pharmaceutically-produced and uniform oil products to patients in Denmark, Sweden, Norway, UK and Australia.

All Stenocare medical cannabis sublingual oil products are produced in accordance with Good Agricultural and Collection Practices (GACP) without the use of pesticides and Good Manufacturing Practice (EU GMP) for Pharmaceutical Products. Stenocare’s products are whole-plant (full spectrum) cannabis-based medicines, that are tested for quality and compliance at external laboratories.

To access the product list, members can login here. Not yet a member?  Join the Medical Cannabis Clinicians Society.